Mirabegron a cost-effective option for OAB treatment in Colombia

Abstract

Mirabegron is cost effective, compared with the oral antimuscarinic agents oxybutynin and tolterodine, for the treatment of adults with overactive bladder (OAB) in Colombia. This is the main finding of a study that used a Markov model with a 5-year time horizon to compare the costs and outcomes of using mirabegron 50mg once daily, compared with oxybutynin extended release (ER) 12mg once daily or tolterodine ER 4mg once daily, in a hypothetical cohort of adults with OAB in Colombia from a third-party payer perspective.* The model showed that oxybutynin ER was the least costly option for all three measures of effectiveness (QALYs, micturition state improvement [MSI] and incontinence state improvement [ISI]), followed by tolterodine ER and mirabegron. However, mirabegron provided the greatest improvement in QALYs and OAB symptoms, followed by tolterodine ER and oxybutynin. Mirabegron was also associated with fewer OAB-related comorbidity events. Mirabegron had an incremental cost-effectiveness ratio of COP85.8 million** per QALY vs oxybutynin ER and COP66.4 million per QALY vs tolterodine ER. Both values are below the COP124.9 million willingness-to-pay (WTP) threshold (i.e., 3 times per-capita GDP). The incremental costs for mirabegron per ISI and per MSI were also well below the WTP threshold. Sensitivity analyses showed that the results were robust, thus strengthening our findings that mirabegron is a cost-effective solution to the treatment of OAB in Colombia, conclude the researchers.